Christ Léna, Kuntz Salomé, Vakhitov Damir, Raibaut Laurent, Neumann Nicole, Heim Frédéric, Chakfé Nabil, Lejay Anne
GEPROMED, Strasbourg, France.
Department of Vascular Surgery, Kidney Transplantation and Innovation, University Hospital of Strasbourg, Strasbourg, France.
J Endovasc Ther. 2024 Aug 27:15266028241274736. doi: 10.1177/15266028241274736.
To understand possible reasons for poor durability of the Nellix (Endologix Inc., Irvine, USA) endovascular aneurysm sealing (EVAS) device.
21 Nellix endoprostheses explanted for endoleaks and migration underwent visual examinations of stent structures and instrumental examinations of the polymer endobags on 4 devices. We harvested 2.0-gram polymer slices out of each of them and tested the samples in an in vitro implantation replication that included wet and dry exposures. During the wet phase, we placed samples in a beaker with saline, mimicking the filling of the endobags during implantation. An exposure to a 37°C environment with 60% humidity during the dry phase replicated the postimplantation conditions inside the aneurysmal sac.
Iatrogenic defects affected 16 (76%) metal stents and 20 (95%) endobags. The polymer was disintegrated owing to degradation in 15 (71%) cases. The polymer could lose more than 70% of its initial weight when partially dehydrated and regain 80% when placed in saline. We observed volume decrease and polymer fragmentation during these study phases.
The polymer can lose weight and volume while it dehydrates. This structural degradation of the polymer could lead to the development of endoleaks and/or migration of the device.
Based on the results of previous investigations, due to possible endovascular device degradation, patients with endografts should be offered life-long surveillance, and the Nellix device is no exception. Herein we suggest polymer degradation as one of the possible reasons for the device failure. Although Nellix has been withdrawn from the market, there are numerous patients with this type of endograft. Due to its unpredictable performance in the medium and long term, these patients should be recommended enhanced life-long surveillance every 6 months. Any suspicious conditions during the follow-up must be taken seriously and explantation should be considered.
了解美国尔湾市Endologix公司的Nellix血管内动脉瘤封堵(EVAS)装置耐久性差的可能原因。
对21个因内漏和移位而取出的Nellix内支架进行了支架结构的目视检查,并对4个装置的聚合物内袋进行了仪器检查。我们从每个装置中取出2.0克聚合物切片,并在包括湿态和干态暴露的体外植入复制实验中对样品进行测试。在湿态阶段,我们将样品置于装有盐水的烧杯中,模拟植入过程中内袋的充盈情况。在干态阶段,将样品置于37°C、湿度60%的环境中,模拟动脉瘤腔内植入后的条件。
医源性缺陷影响了16个(76%)金属支架和20个(95%)内袋。在15个(71%)病例中,聚合物因降解而解体。聚合物在部分脱水时可损失超过70%的初始重量,而置于盐水中时可恢复80%。在这些研究阶段,我们观察到了体积减小和聚合物破碎。
聚合物在脱水时会失重和体积减小。这种聚合物的结构降解可能导致内漏的发生和/或装置的移位。
根据先前的研究结果,由于血管内装置可能发生降解,应建议接受内支架植入的患者进行终身监测,Nellix装置也不例外。在此,我们认为聚合物降解是装置失效的可能原因之一。尽管Nellix已退出市场,但仍有许多患者使用这种类型的内支架。由于其在中长期的性能不可预测,应建议这些患者每6个月进行一次强化终身监测。随访期间任何可疑情况都必须认真对待,并应考虑取出装置。